A Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen Prior to Hematopoietic Cell Transplantation (HSCT)
Latest Information Update: 14 Jul 2021
At a glance
- Drugs Netupitant/palonosetron (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 29 Apr 2020 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2020 Planned End Date changed from 1 May 2019 to 20 Mar 2020.